Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $107.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 9.44% to $107.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.6 million through Dec 2025, down 9.44% year-over-year, with the annual reading at $107.6 million for FY2025, 9.44% down from the prior year.
  • Total Non-Current Liabilities hit $107.6 million in Q4 2025 for Allogene Therapeutics, down from $109.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $152.9 million in Q1 2023 to a low of $97.2 million in Q2 2021.
  • Historically, Total Non-Current Liabilities has averaged $122.0 million across 5 years, with a median of $118.3 million in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 46.5% in 2022 and later dropped 21.65% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $117.8 million in 2021, then increased by 26.32% to $148.8 million in 2022, then fell by 15.74% to $125.4 million in 2023, then decreased by 5.31% to $118.8 million in 2024, then dropped by 9.44% to $107.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ALLO at $107.6 million in Q4 2025, $109.0 million in Q3 2025, and $110.9 million in Q2 2025.